SLE had a greater impact on mortality and other poor outcomes than all the other comorbidities considered in a cross-sectional study of patients with COVID-19 in Brazil.
for the unvaccinated. people said the idea of rationing care, triaging against unvaccinated, all that, i don t think that s what s happening here. hospitals generally take care of everybody. no matter what. i know there has been a lot made of should people who are not vaccinated not get the same level of care. i haven t seen a single hospital system saying that. transplant patients are different. they re often required to be vaccinated against all sorts of different diseases. heb, mmr, things like that, you get a transplant and go on immunosuppressive drugs. so if you haven t been vaccinated against something, you have a much higher chance of contracting the disease you could have been vaccinated against. and that could potentially waste an organ transplant. what the university of colorado has said is there is about a 20% higher chance of dieing if you ve not been vaccinated, subsequently receive an organ transplant and that is what is really driving this. i learned something, i didn
Brad Rovin, MD, and Richard Furie, MD, discussed the merits of dual therapy with voclosporin or belimumab in lupus nephritis but said response rates leave a lot of room for improvement.
:
Key trends in the market include increasing research and development activities, increasing cases of influenza, ongoing clinical trials on plant-based vaccine, inorganic activities such as collaborations by the market players, and others.
Increasing number of research and development activities for improving the effectiveness of plant-based vaccines is expected to bolster growth of the plant-based vaccines market. For instance, on November 10, 2020, Medicago Inc. started conducting clinical trials for the production of plant-based COVID-19 vaccine. The company is planning to initiate Phase II/ III clinical trial after receiving positive results from the Phase I trial. Moreover, Medicago Inc. is also developing VLP Quadrivalent plant-based vaccine for Seasonal Influenza. Currently, the influenza vaccine is in Phase II of the clinical trial. In both the cases, Nicotiana Benthamiana, an Australian tobacco plant, is used for the production of COVID-19 and Influenza vaccine.